Company Of The Day: Boston Scientific

+34.14%
Upside
38.01
Market
50.99
Trefis
BSX: Boston Scientific logo
BSX
Boston Scientific

What?

Boston Scientific (NYSE:BSX) closed its acquisition of Baylis Medical, a company that offers advanced transseptal access solutions and products used to support heart procedures.

Why?

Relevant Articles
  1. What’s Happening With Boston Scientific Stock?
  2. What To Expect From Boston Scientific Stock Following Q1 Earnings?
  3. This Software Company Is Likely To Offer Better Returns Over Boston Scientific Stock
  4. Is Boston Scientific Stock A Good Buy At $43?
  5. What To Expect From Boston Scientific Stock Following Q4 Earnings?
  6. Should You Buy Boston Scientific Stock Over Its Industry Peer?

With the $1.75 billion deal, Boston Scientific will be able to strengthen its position in multiple high-growth cardiology markets.

So What?

We think BSX stock is undervalued at current levels. We value BSX at about $50 per share, about 15% ahead of the current market price.

See Our Complete Analysis For Boston Scientific

What if you’re looking for a more balanced portfolio instead? Here’s a high-quality portfolio that’s beaten the market consistently since the end of 2016.

Returns Feb 2022
MTD [1]
2022
YTD [1]
2017-22
Total [2]
 BSX Return 3% 4% 104%
 S&P 500 Return -1% -6% 100%
 Trefis MS Portfolio Return 2% -8% 264%

[1] Month-to-date and year-to-date as of 2/17/2022
[2] Cumulative total returns since the end of 2016

Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates